People
According to reports, FDA Commissioner Scott Gottlieb will outline the formation of the Office of Drug Evaluation Sciences, a 52-member group, during his talk at the J.P. Morgan Healthcare Conference in San Francisco later today.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
Amgen continues to move toward completing its promise of shifting patients to a cheaper cost of its blockbuster anti-cholesterol drug Repatha, a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor.
In theory, the U.S. Food and Drug Administration (FDA) is tasked with overseeing the safety of food and drugs in the U.S. based on science, not politics. That doesn’t always work.
Applications for the 2019 Boardroom Ready program now open
In a special report published by Reuters last month, Michele Gershberg describes the painstaking medical journey of her 4-year-old son. “It was March 2017. Over the previous year, the signs had mounted that something was wrong.”
Baselga resigned from Memorial Sloan Kettering following reports he failed to disclose his financial ties to various pharma companies in articles he published.
Dr. Dube brings proven track record of global leadership built upon significant commercial and operational success
ADC Therapeutics today announced that Peter Hug, Ph.D., will be appointed to its board of directors. Dr. Hug is a 35-year veteran of Roche.
California’s life science sector is a major player in the state’s job creation and economic development. In 2016, life science companies in California employed more than 360,000 professionals.
PRESS RELEASES